Medical Marijuana, Inc. Subsidiary Kannaway® Achieves Largest Revenue Month in Company History for Japan Division in June 2022
Medical Marijuana, Inc. (OTC: MJNA) announced that its subsidiary, Kannaway®, achieved its largest revenue month in June 2022 for its Japan division, reflecting robust growth since its establishment in 2019. The Japanese CBD market is projected to reach approximately $1.9 billion USD by 2024. CEO Blake Schroeder noted an increase in sales every month this year and potential easing of regulations on CBD sales, which could further enhance market opportunities.
- Kannaway® reported its largest revenue month in history for Japan in June 2022.
- Continuous month-over-month sales growth observed in 2022.
- Japan's CBD market projected to grow to $1.9 billion USD by 2024, indicating significant market potential.
- Possible regulatory easing in Japan may expand sales opportunities.
- None.
SAN DIEGO, CA, July 12, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that in June its subsidiary Kannaway® has achieved its largest revenue month in the Company’s history for its Japan division.
Kannaway® established operations in Japan in 2019 and the company has experienced rapid growth in 2020, 2021 and to date in 2022. Japan’s CBD market is projected to become the second-largest CBD market in Asia, growing to about
“This year has been phenomenal for Kannaway in Japan. The company has increased sales every month in 2022 so far and we look forward to continuing this trend,” said Medical Marijuana, Inc. CEO Blake Schroeder. “Reporting indicates that the Japanese government is considering easing some of its regulations on how CBD is sold in the country, and this would allow for increased opportunity for Kannaway in the marketplace.”
To learn more about Kannaway®, please visit the Company online at https://www.kannaway.com/
About Kannaway®
Kannaway® is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway® currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunities to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products.
About Medical Marijuana, Inc.
We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Neuropathix. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company's flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.
Medical Marijuana, Inc.'s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.'s corporate video, click here.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
LEGAL DISCLOSURE
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
CONTACT:
Public Relations Contact:
Kathryn Brown
Account Director
CMW Media
P. 858-221-8001
kathryn@cmwmedia.com
www.cmwmedia.com
Investor Relations Contact:
P. (858) 283-4016
Investors@medicalmarijuanainc.com
FAQ
What was the revenue achievement for Medical Marijuana, Inc. in June 2022?
What is the growth forecast for Japan's CBD market?
How has Kannaway® performed in sales throughout 2022?
Are there any regulatory changes anticipated for CBD in Japan?
